Belgium cites ethylene oxide impact in recall decline

Almost 400 product recalls and warnings were issued in Belgium in 2022, which is down from the year before.

If a product has reached the market and consumption poses a risk, companies must inform consumers. This happened 394 times in 2022 compared to 492 occasions in 2021, said the Federal Agency for the Safety of the Food Chain (FASFC).

More than 8 out of 10 product recalls in 2022 were caused by the detection of a chemical or microbiological risk.

In 2022, 289 products were recalled from consumers. This decrease of 98 recalls was directly linked to the problem of ethylene oxide which was largely resolved in 2022. However, recalls are still occurring in 2023, mostly in France but also in Germany and the Netherlands.

In 2021, 55 percent of recalls in Belgium were linked to the presence of ethylene oxide, which is not authorized in Europe. This percentage fell to 13 percent in 2022.

In September 2020, ethylene oxide was detected in sesame seeds from India. The substance was later found in other raw materials such as herbs, spices, and locust bean gum, a type of thickening agent used in ice cream and other foods.

In the summer of 2021, European countries moved from zero tolerance to a fine-tuned approach for products containing the substance. When ethylene oxide is found in a raw material, companies have to check whether it will also be in the final product. Only final products containing ethylene oxide above the limit are recalled from consumers.

Other reasons for warnings
The potential presence of a bacterium like Listeria, Salmonella, or Shiga toxin-producing E. coli (STEC) was behind a quarter of product recalls in 2022.

Nearly 6 in 10 recalls were carried out following the detection, by companies or authorities, of a chemical risk, such as too high a content of a pesticide residue or the presence of an unauthorized additive.

A total of 41 recalls were due to contamination by foreign bodies such as pieces of metal or glass.

For each product recall, a poster is put up in stores, and details are published on FASFC’s website and via its social media. The objective is to inform consumers who could have purchased the affected product.

In 2022, as in 2021, 105 allergy alerts had to be issued. The vast majority were concerned about the absence of information on one or more allergens on the packaging.

Companies must report any issues that may impact other companies or the consumer to FASFC. In 2022, the agency received 1,342 notifications from companies, which was a decrease from 1,557 in 2021. For each notification of a potential problem, FASFC investigates and may find it necessary to ask a company to issue a product recall or warning.

The number of alerts involving Belgium in the Rapid Alert System for Food and Feed (RASFF) continued to rise, reaching 749 in 2022.

(To sign up for a free subscription to Food Safety News,click here.)

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Nuts and your heart: Eating nuts for heart health thumbnail

Nuts and your heart: Eating nuts for heart health

Nuts and your heart: Eating nuts for heart healthDiscover how walnuts, almonds and other nuts can help lower cholesterol when eaten as part of a balanced diet.By Mayo Clinic Staff Eating nuts as part of a healthy diet may be good for the heart. Nuts contain unsaturated fatty acids and other nutrients. And they're a
Read More
Which charities does Candis Club support? thumbnail

Which charities does Candis Club support?

We are proud to be involved in the Candis Big Give, a highly inspirational fundraising initiative which has raised thousands of pounds for the health charities involved. Each charity involved chooses a vital project they wanted to see happen and the Candis Big Give helped them achieve the funds they needed.
Read More
Growing Controversy Over 'Skinny' Labeling for Generic Drugs thumbnail

Growing Controversy Over ‘Skinny’ Labeling for Generic Drugs

The vast majority of patients who initiated imatinib therapy for gastrointestinal stromal tumors (GISTs) received a generic drug that did not have FDA approval for that indication, a large retrospective review showed. Almost half of the 2,000 patients in the review of imatinib initiators had chronic myeloid leukemia (CML), while about a third had GIST.…
Read More
Index Of News
Total
0
Share